A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation
Carcinoma, Non-Small-Cell Lung
DRUG: Adagrasib|DRUG: Pembrolizumab|DRUG: Carboplatin|DRUG: Pemetrexed|DRUG: Placebo|DRUG: Cisplatin
Progression Free Survival (PFS) as Assessed per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Blinded Independent Central Review (BICR), Up to 7 years|Overall Survival (OS), Up to 7 years
Overall Response (OR) as Assessed per RECIST v1.1 by BICR, Up to 7 years|Duration of Response (DOR) as Assessed per RECIST 1.1 by BICR, Up to 7 years|PFS as Assessed per RECIST v1.1 by Investigator, Up to 7 years|Number of Participants With Adverse Events (AEs), Up to 90 days from last dose|Number of Participants With Serious Adverse Events (SAEs), Up to 90 days from last dose|Number of Participants With AEs Leading to Dose Interruption, Up to 90 days from last dose|Number of Participants With AEs Leading to Dose Reduction, Up to 90 days from last dose|Number of Participants With AEs Leading to Treatment Discontinuation, Up to 90 days from last dose|Number of Deaths, Up to 90 days from last dose|Time to Definitive Deterioration by Non-Small Cell Lung Cancer-Symptom Assessment Questionnaire (NSCLC-SAQ) Total Score, Up to 7 years|Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-30) Scale/item Score, Up to 90 days from last dose
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation